Guardian Pharmacy Services Inc is a pharmacy services company providing technology-enabled services to help residents of long-term health care facilities (LTCFs) adhere to appropriate drug regimens, reducing the cost of care and improving clinical outcomes. The Company provides high-touch clinical, drug dispensing, and administration services tailored to residents in assisted living facilities, behavioral health facilities, and group homes, while also serving residents in all types of LTCFs. It partners with residents, LTCFs, and health plan payors to help reduce errors in drug administration, manage drug regimens, and improve adherence. The Company derives its revenue mainly from the sale of pharmaceutical and medical products.
Last trade$50.16
Day change+$0.73 (+1.48%)
Day range$48.88 – $50.64
Volume130,720
Market cap$3.13B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.13B
Price / earnings
41.88×
Price / book
11.72×
Price / sales
2.15×
EV / sales
2.07×
EV / EBITDA
25.61×
Profitability
Earnings per share
$1.18
Return on assets
15.2%
Return on equity
27.98%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.65×
Quick ratio
1.33×
Cash ratio
0.67×
Cash flow
Price / cash flow
27.46×
Price / free cash flow
28.71×
Free cash flow
$109.09M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GRDN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$371.07M
$351.77M
$336.6M
$397.62M
$377.43M
$344.33M
$329.31M
$338.57M
Cost of revenue
$285.85M
$271.72M
$260.29M
$312.11M
$302.71M
$276.19M
$264.96M
$271.47M
Gross profit
$85.22M
$80.04M
$76.31M
$85.5M
$74.72M
$68.15M
$64.35M
$67.1M
Selling, general and administrative
$60.16M
$59.4M
$58.63M
$54.74M
$58.37M
$55.57M
$51.34M
$50.35M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$60.16M
$59.4M
$58.63M
$54.74M
$58.37M
$55.57M
$51.34M
$50.35M
Operating income
$25.06M
$20.64M
$17.68M
$30.76M
$16.35M
$12.58M
$13.01M
$16.76M
Interest expense
-$177K
-$154K
-$154K
-$163K
-$160K
-$172K
-$170K
-$421K
Income before taxes
$25.98M
$29.79M
$18.29M
$31.1M
$16.63M
$12.59M
$13.11M
$16.22M
Income taxes
$6.86M
$7.67M
$4.75M
$9.83M
$7.04M
$3.76M
$3.83M
$4.38M
Net income
$19.12M
$22.12M
$13.54M
$21.27M
$9.59M
$8.83M
$9.27M
$11.84M
Net income attributable to common shareholders
$18.68M
$21.87M
$13.3M
$20.92M
$9.82M
$9.03M
$9.45M
$11.94M
EBITDA
$31M
$26.45M
$23.65M
$36.5M
$22.19M
$18.07M
$18.27M
$21.91M
Basic earnings per share
$0.29
$0.35
$0.21
$0.33
$0.16
$0.15
$0.15
$0.06
Diluted earnings per share
$0.29
$0.34
$0.21
$0.33
$0.15
$0.14
$0.15
$0.06
Recent news
Company coverage with links to the original publishers.
In a comparison of two Medical-Drugs sector stocks, Neurocrine Biosciences (NBIX) emerges as the superior value opportunity over Guardian Pharmacy Services (GRDN). NBIX holds a Zacks Rank #2 (Buy) with stronger valuation metrics including a forward P/E of 16.46 versus GRDN's 35.76, a PEG ratio of 0.56 versus 2.20, and a P/B ratio of 4.41 versus 8.37. NBIX also received a Value grade of B compared to GRDN's C grade.
In a comparison of two Medical-Drugs sector stocks, Neurocrine Biosciences (NBIX) emerges as the superior value option over Guardian Pharmacy Services (GRDN). NBIX holds a Zacks Rank #2 (Buy) with a Value grade of B, featuring a forward P/E of 16.05 and PEG ratio of 0.55, while GRDN has a Zacks Rank #3 (Hold) with a Value grade of C, boasting a forward P/E of 32.48 and PEG ratio of 2.00. NBIX's stronger earnings outlook and more attractive valuation metrics make it the preferred choice for value investors.
Guardian Pharmacy Services reported Q3 2026 earnings of $0.33 per share, beating consensus estimates of $0.32, with revenues of $371.07 million exceeding expectations by 1.96%. The company has surpassed consensus EPS estimates in all four of the last quarters. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
U.S. stock futures declined on Thursday as markets processed the Federal Reserve's decision to maintain interest rates at 3.50%-3.75%. Geopolitical tensions escalated as President Trump warned Iran against strikes on Qatar's LNG facilities. Key stocks in focus include Micron Technology, FedEx, Constellation Energy, and Guardian Pharmacy Services, with mixed performance across sectors.